The first cancer vaccines matched to a person’s unique tumor neoantigens are forging ahead, with expectations running high as the field awaits results from the first pivotal trial.
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
195,33 € per year
only 16,28 € per issue
Buy this article
Prices may be subject to local taxes which are calculated during checkout
Sheridan, C. Individualized mRNA cancer vaccines make strides.
Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02708-7
Published:
DOI: https://doi.org/10.1038/s41587-025-02708-7